Business
Butterfly Network is built around an Ultrasound-on-Chip semiconductor platform for point-of-care ultrasound hardware, software, services, and education.
Butterfly grew revenue and sharply reduced cash burn, but losses persisted and Altman-Z remained in distress.
The read at a glance✓ Audited against SEC data
- Business mix — Semiconductor-based point-of-care ultrasoundNote
- Revenue — $97.6M, up 19.0%OK
- Losses — Net loss widened to $77.1MWatch
- Cash — Free cash flow improved to -$16.0MOK
- Margins — Gross margin fell to 46.9%Watch
- Insiders — 9 purchases / 37 salesNote
- Accounting — Altman-Z distress; Beneish-M and earnings-quality safeWatch
Where the revenue comes from
Fiscal 2025, as Butterfly Network, Inc. reports it. History and quarterly detail are in the app.
- Devices and accessories$63.4M
- Software and other services$34.2M
Leadership changes
From Butterfly Network, Inc.'s own filings, the day they're filed.
- Caroll H. Neubauer · director · appointmenteff. 2026-05-07
- S. Senate · President · departureeff. 2026-05-07
- John Doherty · Chief Financial Officer · departureeff. 2025-12-08
Latest filings
- 8-K · Company announcement2026-08-11
- 8-K · Company announcement2026-07-30
- 10-Q · Quarterly report2026-07-30
- 8-K · Company announcement2026-06-22
- 8-K · Company announcement2026-05-08
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Butterfly Network, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.